NMT1 and neoplasm: At the conclusion of treatment, we measured NMT activity21 in BL2 tumor lysates and find it to be reduced in a PCLX-001 concentration-dependent manner (P = 0.03; Fig. 7c) showing that PCLX-001 acts on target in vivo.